Michel Attal

University of Jordan — JO

Medicine · Health Sciences

105h-index47.7kcitations657works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(409), Protein Degradation and Inhibitors(166), Cancer Treatment and Pharmacology(118), Hematopoietic Stem Cell Transplantation(99), Peptidase Inhibition and Analysis(90)

Publications654 total

Environmental Risk Factors for Inflammatory Bowel Diseases in Jordan: A Matched Case–control Study
JAP Academy Journal·2025Open Access
Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone (<scp>IRd</scp>) combination followed by extended <scp>IRd</scp> consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03
British Journal of Haematology·2024· 3 citedOpen Access
Figure S1 from Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study
2023Open Access
Supplementary Figures from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Figure S1 from Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study
2023Open Access
Figure S2 from Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study
2023Open Access
Supplementary Tables from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Supplementary Table 4 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
2023Open Access
Supplementary Table 2 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
2023Open Access
Supplementary Figures from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
2023Open Access
Supplementary Figures from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Supplementary Table 3 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
2023Open Access
Supplementary Table 1 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
2023Open Access
Data from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Supplementary Table 4 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
2023Open Access
Data from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
2023Open Access
Data from Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study
2023Open Access
Data from Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study
2023Open Access
Supplementary Table 2 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
2023Open Access
Data from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
page 1 of 33Next →

Frequent Co-authors

Philippe Moreau(34), Thierry Façon(31), Hervé Avet‐Loiseau(25), Denis Caillot(16), Kenneth C. Anderson(15), Michèle Cavo(15), Jean‐Luc Harousseau(15), Meletios Α. Dimopoulos(14), Jesús F. San Miguel(13), Paul G. Richardson(13), Cyrille Hulin(13), Gérald Marit(13), Xavier Leleu(12), Lotfi Benboubker(12), Pieter Sonneveld(11), Brigitte Pegourié(11), Heinz Ludwig(10), Claire Mathiot(10), Cyrille Hulin(10), Sagar Lonial(9)